Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities

Milica Vukotić, Suncica Kapor, Felipe Simon, Vladan Cokic, Juan F. Santibanez

Research output: Contribution to journalReview articlepeer-review

Abstract

Myeloid malignancies are clonal disorders of the progenitor cells or hematopoietic stem cells, including acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid neoplastic cells affect the proliferation and differentiation of other hematopoietic lineages in the bone marrow and peripheral blood, leading to severe and life-threatening complications. Mesenchymal stromal cells (MSCs) residing in the bone marrow exert immunosuppressive functions by suppressing innate and adaptive immune systems, thus creating a supportive and tolerant microenvironment for myeloid malignancy progression. This review summarizes the significant features of MSCs in myeloid malignancies, including their role in regulating cell growth, cell death, and antineoplastic resistance, in addition to their immunosuppressive contributions. Understanding the implications of MSCs in myeloid malignancies could pave the path for potential use in immunotherapy.

Original languageEnglish
Article numbere25081
JournalHeliyon
Volume10
Issue number3
DOIs
Publication statusPublished - 15 Feb 2024

Keywords

  • Cell differentiation
  • Mesenchymal stromal cells
  • Myeloid cells
  • Myeloid malignancies
  • T-cell immunosuppression therapy

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities'. Together they form a unique fingerprint.

Cite this